Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics
Open Access
- 2 February 2022
- journal article
- letter
- Published by Wiley in Hematological Oncology
- Vol. 40 (3) , 469-474
Abstract
Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid‐19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase‐free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid‐19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid‐19 era, because of the self‐administration at home which results in improvement in the QoL and reduced treatment expenditures.Keywords
This publication has 26 references indexed in Scilit:
- Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency diseaseClinical and Experimental Immunology, 2015
- Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapiesClinical and Experimental Immunology, 2014
- Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patientsHaematologica, 2014
- Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?Journal of Clinical Immunology, 2014
- Bioavailability of IgG Administered by the Subcutaneous RouteJournal of Clinical Immunology, 2013
- Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2012
- Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyJournal of Allergy and Clinical Immunology, 2012
- Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approachesBest Practice & Research Clinical Haematology, 2010
- Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantationCochrane Database of Systematic Reviews, 2008
- The immunodeficiency of chronic lymphocytic leukaemiaBritish Medical Bulletin, 2008